BD (NYSE: BDX) plans to close a facility in Caesarea, Israel, by the middle of the year.
Calcalist’s CTech out of Israel reported the news earlier today, saying that the closure affects 200 employees who will be let go. BD acquired the facility through its 2017 acquisition of Caesarea Medical Electronics, maker of infusion and syringe pumps and accessories for home and clinic settings.
In a statement shared by a spokesperson with MassDevice, the company confirmed the news:
BD continuously reviews its global manufacturing and supply chain network to optimize operations and better serve our customers worldwide. After a thorough review, BD has determined that we can more efficiently meet our customer and capacity needs by utilizing other facilities, and we have made the decision to transition all manufacturing from Caesarea Medical Electronics Ltd (CME) in Israel to other existing BD locations.
We fully understand the impact this project may have on our dedicated employees. The decision to initiate this project does not reflect their outstanding work. BD is committed to supporting any affected employees during the transition, which will continue through June 2025. We will actively work to identify potential opportunities for them within BD’s other operations or through job placement assistance. Our goal is to ensure that each person is treated with dignity and receives the support they need.
The news comes more than a week after BD announced it would invest further in U.S. manufacturing, boosting its capacity of domestically manufactured, safety-engineered injection devices by more than 40%, with conventional syringes increasing by more than 50%. The company said increased capacity adds more than 215 full-time employees at plants in Nebraska and Connecticut.
